The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are:
Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:
* Serum Activin A,
* Serum Nostrin,
* Serum Angiopoetin-2
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients 18 years and older of age requiring hemodialysis for acute kidney injury
Exclusion Criteria:
* Patients under 18 years of age
* Patients under chronic renal replacement therapy
* Patients with a history of renal transplantation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study tracked markers like nostrin, activin A, and angiopoietin-2 in patients on hemodialysis for acute kidney injury — has my care team considered testing any of these markers to help predict how my kidneys might recover or what my risk level looks like?
2Since this trial is now completed and was measuring whether these vascular markers could predict who successfully weans off hemodialysis versus who doesn't, are there any published findings from it that might be relevant to my own situation?
3The study focused specifically on patients with acute kidney injury who needed hemodialysis — given that this matches my condition, is there anything from this type of research that's already influencing how my doctors are monitoring my prognosis?
4This was an observational study measuring biomarkers rather than testing a new treatment, so it wouldn't have changed what care patients received — does that mean the value for me is more about better predicting outcomes than about a new therapy option?
5Are there any other studies or clinical pathways my doctor is aware of that are now testing treatments based on these kinds of vascular markers in AKI patients, since this trial was focused on prediction rather than intervention?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD)
Timeframe: From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)